UiPath Inc. (NYSE:PATH - Get Free Report)'s stock price shot up 0.7% during mid-day trading on Wednesday . The company traded as high as $20.25 and last traded at $20.04. 1,344,226 shares changed hands during trading, a decline of 83% from the average session volume of 8,009,688 shares. The stock had previously closed at $19.90.
Wall Street Analysts Forecast Growth
A number of research firms recently issued reports on PATH. Evercore ISI boosted their price objective on UiPath from $24.00 to $27.00 and gave the company an "in-line" rating in a research note on Thursday, March 14th. BMO Capital Markets boosted their price objective on UiPath from $24.00 to $28.00 and gave the company a "market perform" rating in a research note on Thursday, March 14th. Needham & Company LLC reiterated a "buy" rating and set a $30.00 price objective on shares of UiPath in a research note on Wednesday, March 20th. Truist Financial reiterated a "buy" rating and set a $32.00 price objective on shares of UiPath in a research note on Wednesday, March 20th. Finally, Barclays boosted their price objective on UiPath from $23.00 to $25.00 and gave the company an "equal weight" rating in a research note on Friday, March 15th. Nine investment analysts have rated the stock with a hold rating and nine have given a buy rating to the company. According to MarketBeat, UiPath has a consensus rating of "Moderate Buy" and a consensus price target of $27.41.
Check Out Our Latest Stock Report on PATH
UiPath Stock Performance
The stock has a market capitalization of $11.15 billion, a P/E ratio of -117.88 and a beta of 1.01. The firm has a 50-day moving average price of $20.88 and a 200 day moving average price of $22.09.
UiPath (NYSE:PATH - Get Free Report) last issued its earnings results on Wednesday, March 13th. The healthcare company reported $0.06 earnings per share for the quarter, beating the consensus estimate of ($0.04) by $0.10. The company had revenue of $405.25 million during the quarter, compared to analysts' expectations of $383.32 million. UiPath had a negative return on equity of 3.29% and a negative net margin of 6.87%. On average, equities analysts anticipate that UiPath Inc. will post -0.04 earnings per share for the current fiscal year.
Insiders Place Their Bets
In other news, CFO Ashim Gupta sold 40,000 shares of the firm's stock in a transaction that occurred on Thursday, April 4th. The stock was sold at an average price of $21.66, for a total value of $866,400.00. Following the completion of the transaction, the chief financial officer now owns 660,762 shares in the company, valued at approximately $14,312,104.92. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. In the last 90 days, insiders sold 96,000 shares of company stock worth $2,023,440. 22.37% of the stock is currently owned by company insiders.
Institutional Trading of UiPath
Institutional investors and hedge funds have recently modified their holdings of the business. Mark Sheptoff Financial Planning LLC bought a new stake in shares of UiPath in the 4th quarter worth $25,000. HighMark Wealth Management LLC bought a new stake in shares of UiPath in the fourth quarter worth $27,000. Cypress Capital Management LLC WY bought a new stake in shares of UiPath in the fourth quarter worth $29,000. ORG Partners LLC grew its holdings in shares of UiPath by 875.6% in the first quarter. ORG Partners LLC now owns 1,239 shares of the healthcare company's stock worth $27,000 after acquiring an additional 1,112 shares during the period. Finally, GAMMA Investing LLC bought a new stake in shares of UiPath in the fourth quarter worth $36,000. Institutional investors own 62.50% of the company's stock.
About UiPath
(
Get Free Report)
UiPath Inc provides an end-to-end automation platform that offers a range of robotic process automation (RPA) solutions primarily in the United States, Romania, the United Kingdom, the Netherlands, and internationally. The company offers a suite of interrelated software to build, manage, run, engage, measure, and govern automation within the organization.
Featured Articles
Before you consider UiPath, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and UiPath wasn't on the list.
While UiPath currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Thinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
